IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(s): ESTEVE-SOLER, et al.

SERIAL NO.: ART UNIT:

FILING DATE: Herewith EXAMINER:

TITLE: USE OF 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS

FOR THE TREATMENT OF DISORDERS BASED ON AN IMPAIRMENT OF NO PRODUCTION AND/OR OF

REGULATION OF EDHF FUNCTION

ATTORNEY

DOCKET NO.: 785-012247-US (PAR)

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b)(2))

Sir:

This information disclosure statement is being filed within three months of the date of entry of the national stage as set forth in \$1.491 in an international application.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application.

The above-identified patent application has a counter part PCT patent application No. PCT/EP2003/013468. Applicant's attorney encloses a copy of an International Search Report issued on April 22, 2004 for the counter part application. The International Search Report cites several references, listed below, that are being disclosed to the Patent and Trademark Office as information

that may be material to the examination of the above-identified patent application.

US 4,871,742

US 6,290,990 B1

US 4,513,007

US 4,511,557

WO 97/37647

WO 95/08992

DE 100 16 356 A1

EP 0 204 987

FR 2 656 525

"Calcium Dobesilate: Pharmacological Profile Related to its Use in Diabetic Retinopathy", P. Berthet, et al., IJCP, December 1999, Vol. 53, No. 8, 631-636

"Calcium Dobesilate: Pharmacology and Future Approaches", T. Tejerina, et al., Gen. Pharmac. Vol. 31, No. 3, pp. 357-360, 1998

"Effects of Calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta", E. Ruiz, et al., British Journal of Phamacology (1997) 121, 711-716

"Calciumdobesilat", Aus Anderen Zeitschriften, 292-293

"Calcium Dobesilate in Diabetic Retinopathy - A Retrospective Controlled Study", Christian Adank, et al., Ophthalmologica,
Basel 190: 102-111 (1985)

"Diabetes Mellitus", Nephrology Dialysis Transplantation, Vol. 16, N. 6, 2001, A78

. ;

"Die therapeutische Beeinflußbarkeit der Endstrombahn", H. Bohme,
Therapiewoche Heft 37/1975, 5002-5007

"Calcium dobesilate and its effects on hemorheology and microcirculation", P. Kortringer, et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, Vol. 26 No. 10
- 1998 pp.500-502

"Visualization of Microcirculatory Disorders in Haemorrhagic Fever with Renal Syndrome", B.Z. Sirotin, et al., Nephrol Dial Transplant, 1996 11:721-722

"Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries", Javier Angulo, et al., British Journal of Pharmacology (2003) 139, 854-862

"Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF", Javier Angulo, et al., Biochemical and Biophysical Research Communications 312 (2003) 1202-1208

Copies of these references are enclosed together with a Form PTO-1449 for the Examiner's use.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

10/536780 JC13 Rec'd PCT/PTO 2.6 MAY 2005

Respectfully submitted,

Geza C. Ziegler, Reg. No. 44,004

PERMAN & GREEN, LLP 425 Post Road Fairfield, CT 06824 Customer No. 2512

INFORMATION DISCLOSURE **CITATION FORM FOR** PATENT APPLICATION

Docket No.: 785-012247-US (PAR)

JC13 Rec'd PCT/PTO 2 6 MAY 2009
Applicant(s): Esteve-Soler, et al.

| (FORM PTO-1449) (Substitute) | | | | | | | |
|------------------------------|--|---------------------|-------------------------------------|--------------|-------------------------------------|----------------|----------------|
| | | | Filing Date: Herewith | | Group: | | |
| | | | U.S. PATENTS | | | | : |
| Initials | Patent Number | Issue Date | Name | | Class | Sub- class | Filing date |
| | 4,871,742 | 10/3/89 | Bonne et al. | | 514 | 262 | 12/4/87 |
| | 6,290,990 | 9/18/01 | Grabowski et al. | 424 | 499 | 4/15/95 | |
| | 4,513,007 | 4/23/85 | de Courten et al. | | 514 | 555 | 5/3/83 |
| | 4,511,557 | 4/16/85 | Gauri . | | 514 | 263 | 8/20/82 |
| | | | U.S. PATENT PUBLICAT | IONS | | | |
| Initials | Publication No. | Pub. Date | Name | | Class | Sub- class | Filing Date |
| | | FOI | REIGN PATENT DOCUME | 'NTS | | | |
| Initials | Document Number | Date | Country | 7113 | Nam | <u>е</u> | Translation? |
| muais | Document Number | Date | Country | | | | Yes/No/n/a |
| | WO 97/37647 10/16/97 | | | | atorios D | N/A | |
| | | | | | , S.A. | · | |
| | WO 95/08992 | 4/6/95 | PCT | | r, Christi | No | |
| | DE 100 16 356 A1 | 10/4/01 | Germany | | Gunthe | No | |
| | EP 0 204 987 | 5/15/86 | Europe | | Roshdy | No | |
| | FR 2 656 525 | 7/5/91 | France | | nde (S.A | No | |
| | | | NTS (Title, Author, Date, P | | | | |
| | "Calcium Dobesilate: Pharmacological Profile Related to its Use in Diabetic Retinopathy", P. Berthet, et al., IJCP, | | | | | | |
| | December 1999, Vol. 53, No. 8, 631-636 | | | | | | |
| | "Calcium Dobesilate: Pharmacology and Future Approaches", T. Tejerina, et al., Gen. Pharmac. Vol. 31, No. 3, pp. 357-360, 1998 | | | | | | |
| | "Effects of Calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated | | | | | | |
| | aorta", E. Ruiz, et al., British Journal of Phamacology (1997) 121, 711-716 | | | | | | |
| | "Calciumdobesilat", Aus Anderen Zeitschriften, 292-293 | | | | | | |
| | "Calcium Dobesilate in Diabetic Retinopathy – A Retrospective Controlled Study", Christian Adank, et al., | | | | | | |
| | Ophthalmologica, Basel 190: 102-111 (1985) | | | | | | |
| | "Diabetes Mellitus", Nephrology Dialysis Transplantation, Vol. 16, N. 6, 2001, A78 | | | | | | |
| | "Die therapeutische Beeinflußbarkeit der Endstrombahn", H. Bohme, Therapiewoche Heft 37/1975, 5002-5007 | | | | | | |
| | "Calcium dobesilate and its effects on hemorheology and microcirculation", P. Kortringer, et al., International | | | | | | |
| | Journal of Clinical Pharmacology, Therapy and Toxicology, Vol. 26 No. 10 – 1998 pp.500-502 | | | | | | |
| | "Visualization of Microcirculatory Disorders in Haemorrhagic Fever with Renal Syndrome", B.Z. Sirotin, et al., | | | | | | |
| | Nephrol Dial Transplant, 1996 11:721-722 | | | | | | |
| | "Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile | | | | | | |
| | resistance arteries", Javier Angulo, et al., British Journal of Pharmacology (2003) 139, 854-862 | | | | | | |
| | "Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and | | | | | | |
| | EDHF", Javier Angul | o, et al., Bioch | emical and Biophysical Research | n Commun | Communications 312 (2003) 1202-1208 | | |
| Examin | er's Signature: | | | Date C | Considere | ed: | |
| | | ered, whether or | not citation is in conformance with | MPEP. Mar | k through | citation if no | ot considered. |
| | Include a | a copy of this cita | ation form with your next correspon | dence to the | Applican | t(s). | P |

Customer No.: 2512